Seminars in Liver Disease,
Год журнала:
2024,
Номер
44(02), С. 159 - 179
Опубликована: Май 1, 2024
Primary
liver
cancer,
represented
mainly
by
hepatocellular
carcinoma
(HCC)
and
intrahepatic
cholangiocarcinoma
(CCA),
is
one
of
the
most
common
deadliest
tumors
worldwide.
While
surgical
resection
or
transplantation
are
best
option
in
early
disease
stages,
these
often
present
advanced
stages
systemic
treatment
required
to
improve
survival
time.
The
emergence
immune
checkpoint
inhibitor
(ICI)
therapy
has
had
a
positive
impact
especially
on
cancers,
thereby
establishing
immunotherapy
as
part
first-line
HCC
CCA.
Nevertheless,
low
response
rates
reflect
usually
cold
immunosuppressed
tumor
microenvironment
primary
cancer.
In
this
review,
we
aim
summarize
mechanisms
resistance
leading
escape
with
special
focus
composition
both
CCA,
also
reflecting
recent
important
developments
ICI
combination
therapy.
Furthermore,
discuss
how
ICIs
established
cancer
treatments
(e.g.
multikinase
inhibitors
chemotherapy)
well
more
complex
combinations
state-of-the-art
therapeutic
concepts
may
reshape
microenvironment,
higher
long-lasting
antitumor
immunity
for
patients.
Technology in Cancer Research & Treatment,
Год журнала:
2023,
Номер
22
Опубликована: Янв. 1, 2023
Hepatocellular
carcinoma
(HCC)
is
the
most
common
liver
cancer.
It
highly
lethal
and
has
high
recurrence.
Death
among
HCC
patients
occur
mainly
due
to
tumor
progression,
recurrence,
metastasis,
chemoresistance.
Cancer
stem
cells
(CSCs)
are
cell
subpopulations
within
that
promote
invasion,
drug
resistance.
Hepatic
stellate
(HSCs)
important
components
of
microenvironment
(TME)
responsible
for
primary
secretory
ECM
proteins
during
injury
inflammation.
These
fibrogenesis,
infiltrate
stroma,
contribute
development.
Interactions
between
HSC
CSC
their
help
carcinogenesis
through
different
mechanisms.
This
review
summarizes
roles
CSCs
HSCs
in
establishing
TME
tumors
describes
involvement
Cell Reports Medicine,
Год журнала:
2023,
Номер
4(6), С. 101052 - 101052
Опубликована: Май 23, 2023
Primary
liver
cancer
is
a
rising
cause
of
deaths
in
the
US.
Although
immunotherapy
with
immune
checkpoint
inhibitors
induces
potent
response
subset
patients,
rates
vary
among
individuals.
Predicting
which
patients
will
respond
to
great
interest
field.
In
retrospective
arm
National
Cancer
Institute
Cancers
Liver:
Accelerating
Research
Immunotherapy
by
Transdisciplinary
Network
(NCI-CLARITY)
study,
we
use
archived
formalin-fixed,
paraffin-embedded
samples
profile
transcriptome
and
genomic
alterations
86
hepatocellular
carcinoma
cholangiocarcinoma
prior
following
inhibitor
treatment.
Using
supervised
unsupervised
approaches,
identify
stable
molecular
subtypes
linked
overall
survival
distinguished
two
axes
aggressive
tumor
biology
microenvironmental
features.
Moreover,
responses
treatment
differ
between
subtypes.
Thus,
heterogeneous
may
be
stratified
status
indicative
inhibitors.
International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(13), С. 10910 - 10910
Опубликована: Июнь 30, 2023
Cancer
remains
a
leading
cause
of
death
globally,
and
its
complexity
poses
significant
challenge
to
effective
treatment.
stem
cells
their
markers
have
become
key
players
in
tumor
growth
progression.
CD133,
marker
various
cancer
types,
is
an
active
research
area
as
potential
therapeutic
target.
This
article
explores
the
role
CD133
treatment,
beginning
with
overview
statistics
explanation
markers.
The
rise
discussed,
including
structure,
functions,
occurrence
different
types.
Furthermore,
covers
target,
focusing
on
gene
therapy,
immunotherapy,
approaches
affect
expression.
Nanoparticles
such
gold
nanoparticles
nanoliposomes
are
also
discussed
context
CD133-targeted
therapy.
In
conclusion,
promising
target
for
As
this
progresses,
it
hoped
that
therapies
will
offer
new
treatment
options
patients
future.
Seminars in Liver Disease,
Год журнала:
2024,
Номер
44(02), С. 159 - 179
Опубликована: Май 1, 2024
Primary
liver
cancer,
represented
mainly
by
hepatocellular
carcinoma
(HCC)
and
intrahepatic
cholangiocarcinoma
(CCA),
is
one
of
the
most
common
deadliest
tumors
worldwide.
While
surgical
resection
or
transplantation
are
best
option
in
early
disease
stages,
these
often
present
advanced
stages
systemic
treatment
required
to
improve
survival
time.
The
emergence
immune
checkpoint
inhibitor
(ICI)
therapy
has
had
a
positive
impact
especially
on
cancers,
thereby
establishing
immunotherapy
as
part
first-line
HCC
CCA.
Nevertheless,
low
response
rates
reflect
usually
cold
immunosuppressed
tumor
microenvironment
primary
cancer.
In
this
review,
we
aim
summarize
mechanisms
resistance
leading
escape
with
special
focus
composition
both
CCA,
also
reflecting
recent
important
developments
ICI
combination
therapy.
Furthermore,
discuss
how
ICIs
established
cancer
treatments
(e.g.
multikinase
inhibitors
chemotherapy)
well
more
complex
combinations
state-of-the-art
therapeutic
concepts
may
reshape
microenvironment,
higher
long-lasting
antitumor
immunity
for
patients.
